These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 26170629

  • 1. Siltuximab (CNTO 328): a promising option for human malignancies.
    Chen R, Chen B.
    Drug Des Devel Ther; 2015; 9():3455-8. PubMed ID: 26170629
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Siltuximab for multicentric Castleman disease.
    Liu YC, Stone K, van Rhee F.
    Expert Rev Hematol; 2014 Oct; 7(5):545-57. PubMed ID: 25110138
    [Abstract] [Full Text] [Related]

  • 4. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
    Karkera J, Steiner H, Li W, Skradski V, Moser PL, Riethdorf S, Reddy M, Puchalski T, Safer K, Prabhakar U, Pantel K, Qi M, Culig Z.
    Prostate; 2011 Sep 15; 71(13):1455-65. PubMed ID: 21321981
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
    Ferrario A, Merli M, Basilico C, Maffioli M, Passamonti F.
    Expert Opin Investig Drugs; 2017 Mar 15; 26(3):367-373. PubMed ID: 28140696
    [Abstract] [Full Text] [Related]

  • 7. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer.
    Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B.
    Br J Cancer; 2010 Oct 12; 103(8):1154-62. PubMed ID: 20808314
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R.
    Oncotarget; 2015 Oct 06; 6(30):30408-19. PubMed ID: 26327301
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Siltuximab (Sylvant) for treatment of multicentric castleman's disease.
    Med Lett Drugs Ther; 2015 Jan 05; 57(1459):e8. PubMed ID: 25555075
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
    Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Hall B, van de Velde H, Vermeulen J, Reddy M, van Rhee F.
    Clin Cancer Res; 2015 Oct 01; 21(19):4294-304. PubMed ID: 26124203
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-6 as a therapeutic target in human ovarian cancer.
    Coward J, Kulbe H, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, Schioppa T, Nemeth J, Vermeulen J, Singh N, Avril N, Cummings J, Rexhepaj E, Jirström K, Gallagher WM, Brennan DJ, McNeish IA, Balkwill FR.
    Clin Cancer Res; 2011 Sep 15; 17(18):6083-96. PubMed ID: 21795409
    [Abstract] [Full Text] [Related]

  • 19. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328.
    Steiner H, Cavarretta IT, Moser PL, Berger AP, Bektic J, Dietrich H, Zaki MH, Nakada M, Hobisch A, Nemeth JA, Culig Z.
    Prostate; 2006 Dec 01; 66(16):1744-52. PubMed ID: 16998813
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.